Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.

Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.

Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.

Abstract: Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, DC-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel. The pharmaceutical composition can be used to treat a subject, for example, a human subject having cancer.

Abstract: A pharmaceutical composition can include a plurality of liposomes comprising docetaxel and doxorubicin. In various embodiments, a liposome can include (i) an active pharmaceutical ingredient (API) comprising docetaxel and doxorubicin; (ii) a lipid layer comprising an unsaturated phospholipid, a cholesterol, a cationic lipid, and preferably a pegylated phospholipid; and (iii) an aqueous interior, wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior. The liposomes can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer.

Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.

Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.

Abstract: The present invention relates to a system of individually and separately displaying and sharing of video/audio that is used in an vehicle, comprises: a primary video/audio device having a micro processor, a storing device for storing various of digital video/audio information owned by a user for displaying in secondary video/audio devices and a network interface, the primary video/audio device provides at least one service of displaying digital video/audio information; and a plurality of secondary video/audio devices, each of the secondary video/audio devices is provided with a digital video/audio encoding device, a network interface, a display panel or a video/audio output interface and an operation interface, and the operation interface is provided with a display key and a share key; each of the secondary video/audio devices can individually and at-any-time applies a service request to the primary video/audio device and obtains a related service, such as video/audio displaying, or one of the secondary video

Abstract: A fabric with polyester/polyamide bi-components microfibers may include a warp knitted double-sided base fabric with polyester/polyamide bi-components microfibers that is treated by a chemical splitting process. Both sides of the double-sided base fabric may have at least 10 loop piles per square centimeter. Each loop pile may have at least one single thread loop. The bottom of the loop piles may be connected to the base fabric. The loops may be arranged orderly to form a planar structure that has the feature that the loop piles on one side of the base fabric may have plush-like structures at the top sections. The loops may be fractured by sanding the loops with a sand paper of 200-600 grits at about 1/10 to 5/10 of a thickness of the loop piles to form the plush-like structures.

Abstract: The present invention relates to a system of individually and separately displaying and sharing of video/audio that is used in an vehicle, comprises: a primary video/audio device having a micro processor, a storing device for storing various of digital video/audio information owned by a user for displaying in secondary video/audio devices and a network interface, the primary video/audio device provides at least one service of displaying digital video/audio information; and a plurality of secondary video/audio devices, each of the secondary video/audio devices is provided with a digital video/audio encoding device, a network interface, a display panel or a video/audio output interface and an operation interface, and the operation interface is provided with a display key and a share key; each of the secondary video/audio devices can individually and at-any-time applies a service request to the primary video/audio device and obtains a related service, such as video/audio displaying, or one of the secondary video

Abstract: A computerized method of populating a database composed of rows with applicability fields and parameter fields in a data structure, and of retrieving the data, such that the database may be used to yield relevant results with a minimum of data entries. In a first step, the method defines a hierarchy of applicability fields to suit a particular business model as well as the associated univocal retrieval process. In a second step, the method substitutes unknown applicability fields with a USUB. In a third step, the method prompts the input of appropriate parameter field values for the rows of applicability fields, including those having one or more USUBs. A retrieval method retrieves the data in the data structure. The invention thus enables the population and data retrieval from a database structure such that the database is useful to yield relevant results with a minimum of data entries.

Abstract: Embodiments of the present invention provide methods for inhibiting tumor cell growth, or treating cancer cells, in a subject through the administration of a cathepsin inhibitor or inhibitors. Methods for inhibiting inflammatory disease cells as well as other cathepsin expressing cells in a subject with a cathepsin inhibitor or inhibitors are also within the present invention. Furthermore, the present invention relates to inducing cytotoxicity or apoptosis in cells by administering a cytotoxic or an apoptotic dose of a cathepsin inhibitor or inhibitors to the cell. Finally, the present invention relates to the administering of cathepsin expressing vectors to tumor cells so as to inhibit the tumor cells growth.

Abstract: Embodiments of the present invention provide methods for inhibiting tumor cell growth, or treating cancer cells, in a subject through the administration of a cathepsin inhibitor or inhibitors. Methods for inhibiting inflammatory disease cells as well as other cathepsin expressing cells in a subject with a cathepsin inhibitor or inhibitors are also within the present invention. Furthermore, the present invention relates to inducing cytotoxicity or apoptosis in cells by administering a cytotoxic or an apoptotic dose of a cathepsin inhibitor or inhibitors to the cell. Finally, the present invention relates to the administering of cathepsin expressing vectors to tumor cells so as to inhibit the tumor cells growth.